This is not the most recent version of the article. View current version (21 OCT 2015)

Intervention Protocol

You have free access to this content

Sodium channel blockers for neuroprotection in multiple sclerosis

  1. Chunsong Yang1,
  2. Lingli Zhang2,*,
  3. Zilong Hao3,
  4. Linan Zeng1,
  5. Jin Wen4

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group

Published Online: 28 MAR 2013

DOI: 10.1002/14651858.CD010422


How to Cite

Yang C, Zhang L, Hao Z, Zeng L, Wen J. Sodium channel blockers for neuroprotection in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD010422. DOI: 10.1002/14651858.CD010422.

Author Information

  1. 1

    West China Second University Hospital, Sichuan University, Department of Pharmacy, Chengdu, Sichuan Province, China

  2. 2

    Sichuan University, Department of Pharmacy, West China Second University Hospital, Chengdu, Sichuan, China

  3. 3

    West China Hospital, Sichuan University, Department of Neurology, Chengdu, Sichuan, China

  4. 4

    West China Hospital, Sichuan University, Department of Hospital Management and Health Policy, Chengdu, Sichuan, China

*Lingli Zhang, Department of Pharmacy, West China Second University Hospital, Sichuan University, No. 20, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. zhlingli@sina.com.

Publication History

  1. Publication Status: New
  2. Published Online: 28 MAR 2013

SEARCH

This is not the most recent version of the article. View current version (21 OCT 2015)

References

Additional references

Al-Hashel 2008
Alonso 2008
Bjartmar 2001
Cohen 2012
  • Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurology 2012;11:467-76.
Egger 1997
Etemadifar 2011
Ettinger 2007
Finlayson 2008
Freedman 2011
Gold 2012
  • Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine 2012;367:1098-107.
Goodin 2002
  • Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78.
Herzog 2003
  • Herzog RI, Liu C, Waxman SG, Cummins TR. Calmodulin binds to the C terminus of sodium channels Nav1.4 and Nav1.6 and differentially modulates their functional properties. Journal of Neuroscience 2003;23:8261-70.
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] . The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hyland 2011
Jacobs 1996
Johnson 1995
  • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
Kapoor 2006
Kapoor 2008
Kapoor 2010
  • Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurology 2010;9:681-8.
Kobelt 2006
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
Mantegazza 2010
  • Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurology 2010;9:413-24.
Marrie 2010
McDonald 2001
Miller 2012
Module 2011
  • D'Amico R, Ebers G, Filippini G, Fredrikson S, Di Pietrantonj C, Khan F, et al. Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group. About The Cochrane Collaboration 2011, Issue 1. Art. No.: MS.
National MS Society 2012
  • National MS Society. What we know about MS. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx (accessed 21 October 2012).
Nikolaeva 2005
Polman 2005
Polman 2006
  • Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2006;354:899-910.
Polman 2011
Poser 1983
PRISMS 1998
  • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
Review Manager 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [computer program]. Version 5.1.. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rogawski 2004
Simpson 2011
  • Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry 2011;82:1132-41.
Stys 1992
  • Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. Journal of Neuroscience 1992;12:430-9.
Thompson 2010
Tselis 2010
Vickrey 1995
Ware 1992
Waxman 2008